Short-term administration of intranasal insulin improved episodic memory in patients with Mild Cognitive Impairment and Alzheimer’s Disease, and a placebo-controlled phase 2 and 3 trial showed a better cognitive performance in the insulin treatment group (46). The gene discussed is INS; the disease is early-onset autosomal dominant Alzheimer disease.